Workflow
Amedisys(AMED)
icon
Search documents
Here's Why Amedisys (AMED) is a Strong Momentum Stock
ZACKS· 2024-07-15 14:51
For new and old investors, taking full advantage of the stock market and investing with confidence are common goals. Zacks Premium provides lots of different ways to do both.The popular research service can help you become a smarter, more self-assured investor, giving you access to daily updates of the Zacks Rank and Zacks Industry Rank, the Zacks #1 Rank List, Equity Research reports, and Premium stock screens.Zacks Premium includes access to the Zacks Style Scores as well.What are the Zacks Style Scores?D ...
AMED or USPH: Which Is the Better Value Stock Right Now?
ZACKS· 2024-07-10 16:46
Investors interested in Medical - Outpatient and Home Healthcare stocks are likely familiar with Amedisys (AMED) and U.S. Physical Therapy (USPH) . But which of these two companies is the best option for those looking for undervalued stocks? Let's take a closer look.We have found that the best way to discover great value opportunities is to pair a strong Zacks Rank with a great grade in the Value category of our Style Scores system. The proven Zacks Rank puts an emphasis on earnings estimates and estimate r ...
AMED vs. USPH: Which Stock Should Value Investors Buy Now?
ZACKS· 2024-07-08 17:07
Investors interested in Medical - Outpatient and Home Healthcare stocks are likely familiar with Amedisys (AMED) and U.S. Physical Therapy (USPH) . But which of these two stocks is more attractive to value investors? We'll need to take a closer look to find out.The best way to find great value stocks is to pair a strong Zacks Rank with an impressive grade in the Value category of our Style Scores system. The proven Zacks Rank emphasizes companies with positive estimate revision trends, and our Style Scores ...
Why Amedisys (AMED) is a Top Momentum Stock for the Long-Term
zacks.com· 2024-05-29 14:56
For new and old investors, taking full advantage of the stock market and investing with confidence are common goals. Zacks Premium provides lots of different ways to do both.The research service features daily updates of the Zacks Rank and Zacks Industry Rank, full access to the Zacks #1 Rank List, Equity Research reports, and Premium stock screens, all of which will help you become a smarter, more confident investor.It also includes access to the Zacks Style Scores.What are the Zacks Style Scores?Developed ...
Why Amedisys (AMED) is a Top Value Stock for the Long-Term
zacks.com· 2024-05-28 14:41
Taking full advantage of the stock market and investing with confidence are common goals for new and old investors, and Zacks Premium offers many different ways to do both.The research service features daily updates of the Zacks Rank and Zacks Industry Rank, full access to the Zacks #1 Rank List, Equity Research reports, and Premium stock screens, all of which will help you become a smarter, more confident investor.It also includes access to the Zacks Style Scores.What are the Zacks Style Scores?The Zacks S ...
Why Is Amedisys (AMED) Up 5.5% Since Last Earnings Report?
zacks.com· 2024-05-24 16:39
It has been about a month since the last earnings report for Amedisys (AMED) . Shares have added about 5.5% in that time frame, outperforming the S&P 500.Will the recent positive trend continue leading up to its next earnings release, or is Amedisys due for a pullback? Before we dive into how investors and analysts have reacted as of late, let's take a quick look at the most recent earnings report in order to get a better handle on the important catalysts. Amedisys Q4 Earnings Miss Estimates, Margins RiseAm ...
Amedisys (AMED) Q1 Earnings Surpass Estimates, Margins Rise
Zacks Investment Research· 2024-04-29 13:21
Core Insights - Amedisys, Inc. reported adjusted EPS of $1.03 for Q1 2024, a 3% increase from $1.00 in the same quarter last year, and beat the Zacks Consensus Estimate by 1.9% [1] - Net service revenues reached $571.4 million, reflecting a year-over-year growth of 2.7% and surpassing the Zacks Consensus Estimate by 1.2% [1] Segment Performance - Home Health division generated net service revenues of $364 million, up 6% year over year, with Medicare revenues at $215.8 million (up 0.2%) and non-Medicare revenues at $148.2 million (up 15.9%) [2] - Hospice division reported net service revenues of $201 million, a 3.9% increase year over year, with Medicare revenues at $190 million (up 4%) and non-Medicare revenues at $11 million (up 2.8%) [2] - High Acuity Care segment saw net service revenues of $6.4 million, a significant increase of 36.2% from the previous year [3] Financial Metrics - Gross profit improved by 3.5% to $249.9 million, with gross margin expanding by 35 basis points to 43.7% [4] - Adjusted operating profit rose by 25.9% to $64 million, with adjusted operating margin increasing by 207 basis points to 11.2% [4] Liquidity and Cash Position - Amedisys ended Q1 2024 with cash and cash equivalents of $108.2 million, down from $126.5 million at the end of 2023 [5] - Long-term obligations were $356.1 million at the end of Q1 2024, a slight decrease from $361.9 million at the end of 2023 [5] - Cumulative net cash used by operating activities was $6.5 million, compared to a cash inflow of $26 million a year ago [5] Strategic Outlook - The company is positioned for growth with an impending merger with UnitedHealth Group's Optum, aimed at enhancing value-based care [6] - Despite the positive earnings and revenue results, challenges include wage increases, wage inflation, and shifts in the home health payor mix [6]
Amedisys(AMED) - 2024 Q1 - Quarterly Report
2024-04-25 12:01
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington D.C. 20549 Securities registered pursuant to Section 12(b) of the Act: Title of each class Trading Symbol(s) Name of each exchange on which registered Common Stock, par value $0.001 per share AMED The NASDAQ Global Select Market FORM 10-Q (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended March 31, 2024 or ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECU ...
Compared to Estimates, Amedisys (AMED) Q1 Earnings: A Look at Key Metrics
Zacks Investment Research· 2024-04-25 02:01
Amedisys (AMED) reported $571.41 million in revenue for the quarter ended March 2024, representing a year-over-year increase of 2.7%. EPS of $1.03 for the same period compares to $1.00 a year ago.The reported revenue compares to the Zacks Consensus Estimate of $564.58 million, representing a surprise of +1.21%. The company delivered an EPS surprise of +1.98%, with the consensus EPS estimate being $1.01.While investors scrutinize revenue and earnings changes year-over-year and how they compare with Wall Stre ...
Amedisys (AMED) Q1 Earnings and Revenues Surpass Estimates
Zacks Investment Research· 2024-04-24 23:01
Amedisys (AMED) came out with quarterly earnings of $1.03 per share, beating the Zacks Consensus Estimate of $1.01 per share. This compares to earnings of $1 per share a year ago. These figures are adjusted for non-recurring items.This quarterly report represents an earnings surprise of 1.98%. A quarter ago, it was expected that this home health care and hospice services provider would post earnings of $1.04 per share when it actually produced earnings of $0.94, delivering a surprise of -9.62%.Over the last ...